{"id":9912,"date":"2025-09-29T13:50:09","date_gmt":"2025-09-29T11:50:09","guid":{"rendered":"https:\/\/www.hartwigmedicalfoundation.nl\/?p=9912"},"modified":"2025-09-29T13:50:39","modified_gmt":"2025-09-29T11:50:39","slug":"glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients","status":"publish","type":"post","link":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/","title":{"rendered":"GLOW Study Ends \u2013 But WGS Remains Valuable for Glioblastoma Patients"},"content":{"rendered":"\n

As of October 1, 2025, the GLOW study will officially come to an end. Interim analysis has shown growing enthusiasm among medical specialists for using comprehensive molecular diagnostics in this patient group. Despite identifying potential targets for personalized treatment through Whole Genome Sequencing<\/a> (WGS), only a few patients actually started such targeted therapies. As a result, the primary aim of the study \u2013 demonstrating an improvement in survival \u2013 is no longer attainable.\u00a0<\/strong><\/p>\n\n\n\n

GLOW Results<\/strong> <\/p>\n\n\n\n

The interim analysis of the GLOW study (based on 160 patients) demonstrated that Whole Genome Sequencing (WGS) is feasible in 80% of patients, and potential treatment targets were identified in 32% of cases. However, only a few patients eventually started targeted therapy. The main reasons for not initiating targeted (clinical trial) treatments were the absence of an open study or cohort for the specific target at the time, or the treating physician deemed the target not actionable. <\/p>\n\n\n\n

What Does This Mean for Glioblastoma Patients?<\/strong> <\/p>\n\n\n\n

The conclusion of the GLOW study does not<\/em> mean the end of access to Whole Genome Sequencing (WGS) for glioblastoma patients. In fact, as of June 24, 2025, WGS has been included in the basic healthcare package by the Dutch National Health Care Institute (Zorginstituut Nederland) \u2013 including for the detection of NTRK fusions in second-line treatment. <\/p>\n\n\n\n

We encourage healthcare professionals to actively raise this within their hospitals and in discussions with health insurers. The existing Service Agreement (Dienstverleningsovereenkomst, DVO) under which GLOW operated can generally continue to be used. For questions regarding logistics or billing, please contact Desiree van der Kleij<\/a> at the Hartwig Medical Foundation. <\/p>\n\n\n\n

Next Steps: Targeted Therapy & PePPer Study<\/strong> <\/p>\n\n\n\n

There is strong interest in using WGS for patients with recurrent glioblastoma, and treatable cancer types are regularly identified. To further improve access to targeted therapies, the nationwide PePPer study has recently been approved. More information on this will follow soon. <\/p>\n\n\n\n

Summary<\/strong> <\/p>\n\n\n\n

Although the GLOW study is ending, it has provided valuable insights. WGS remains available as part of standard care for patients with primary brain tumors. With the launch of the PePPer study, we are taking the next step together toward better access to personalized treatments. <\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

As of October 1, 2025, the GLOW study will officially come to an end. Interim analysis has shown growing enthusiasm …<\/p>\n","protected":false},"author":3,"featured_media":9904,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[78,93,85,76,73,82,80],"tags":[],"class_list":["post-9912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-billing-code","category-hartwig-medical-foundation","category-learning-healthcare-system","category-molecular-diagnostics","category-personalized-treatment","category-research","category-whole-genome-sequencing"],"acf":[],"yoast_head":"\nGLOW Study Ends \u2013 But WGS Remains Valuable for Glioblastoma Patients - Hartwig Medical Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GLOW Study Ends \u2013 But WGS Remains Valuable for Glioblastoma Patients - Hartwig Medical Foundation\" \/>\n<meta property=\"og:description\" content=\"As of October 1, 2025, the GLOW study will officially come to an end. Interim analysis has shown growing enthusiasm …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Hartwig Medical Foundation\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T11:50:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-29T11:50:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hartwigmedicalfoundation.nl\/wp-content\/uploads\/2025\/09\/GLOW-logo-EN-zwart-scaled.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1792\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Aleid Eigenraam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Aleid Eigenraam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/\"},\"author\":{\"name\":\"Aleid Eigenraam\",\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/#\\\/schema\\\/person\\\/8cdecf5a8dfc1ee669b684ed6e2b2be1\"},\"headline\":\"GLOW Study Ends \u2013 But WGS Remains Valuable for Glioblastoma Patients\",\"datePublished\":\"2025-09-29T11:50:09+00:00\",\"dateModified\":\"2025-09-29T11:50:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/\"},\"wordCount\":369,\"image\":{\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/GLOW-logo-EN-zwart-scaled.png\",\"articleSection\":[\"Billing code\",\"Hartwig Medical Foundation\",\"Learning healthcare system\",\"Molecular diagnostics\",\"Personalized treatment\",\"Research\",\"Whole genome sequencing\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/\",\"url\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/\",\"name\":\"GLOW Study Ends \u2013 But WGS Remains Valuable for Glioblastoma Patients - Hartwig Medical Foundation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/GLOW-logo-EN-zwart-scaled.png\",\"datePublished\":\"2025-09-29T11:50:09+00:00\",\"dateModified\":\"2025-09-29T11:50:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/#\\\/schema\\\/person\\\/8cdecf5a8dfc1ee669b684ed6e2b2be1\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/GLOW-logo-EN-zwart-scaled.png\",\"contentUrl\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/GLOW-logo-EN-zwart-scaled.png\",\"width\":2560,\"height\":1792},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/#website\",\"url\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/\",\"name\":\"Hartwig Medical Foundation\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/#\\\/schema\\\/person\\\/8cdecf5a8dfc1ee669b684ed6e2b2be1\",\"name\":\"Aleid Eigenraam\",\"url\":\"https:\\\/\\\/www.hartwigmedicalfoundation.nl\\\/en\\\/author\\\/aleid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GLOW Study Ends \u2013 But WGS Remains Valuable for Glioblastoma Patients - Hartwig Medical Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/","og_locale":"en_US","og_type":"article","og_title":"GLOW Study Ends \u2013 But WGS Remains Valuable for Glioblastoma Patients - Hartwig Medical Foundation","og_description":"As of October 1, 2025, the GLOW study will officially come to an end. Interim analysis has shown growing enthusiasm …","og_url":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/","og_site_name":"Hartwig Medical Foundation","article_published_time":"2025-09-29T11:50:09+00:00","article_modified_time":"2025-09-29T11:50:39+00:00","og_image":[{"width":2560,"height":1792,"url":"https:\/\/www.hartwigmedicalfoundation.nl\/wp-content\/uploads\/2025\/09\/GLOW-logo-EN-zwart-scaled.png","type":"image\/png"}],"author":"Aleid Eigenraam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Aleid Eigenraam","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/#article","isPartOf":{"@id":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/"},"author":{"name":"Aleid Eigenraam","@id":"https:\/\/www.hartwigmedicalfoundation.nl\/#\/schema\/person\/8cdecf5a8dfc1ee669b684ed6e2b2be1"},"headline":"GLOW Study Ends \u2013 But WGS Remains Valuable for Glioblastoma Patients","datePublished":"2025-09-29T11:50:09+00:00","dateModified":"2025-09-29T11:50:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/"},"wordCount":369,"image":{"@id":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hartwigmedicalfoundation.nl\/wp-content\/uploads\/2025\/09\/GLOW-logo-EN-zwart-scaled.png","articleSection":["Billing code","Hartwig Medical Foundation","Learning healthcare system","Molecular diagnostics","Personalized treatment","Research","Whole genome sequencing"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/","url":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/","name":"GLOW Study Ends \u2013 But WGS Remains Valuable for Glioblastoma Patients - Hartwig Medical Foundation","isPartOf":{"@id":"https:\/\/www.hartwigmedicalfoundation.nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hartwigmedicalfoundation.nl\/wp-content\/uploads\/2025\/09\/GLOW-logo-EN-zwart-scaled.png","datePublished":"2025-09-29T11:50:09+00:00","dateModified":"2025-09-29T11:50:39+00:00","author":{"@id":"https:\/\/www.hartwigmedicalfoundation.nl\/#\/schema\/person\/8cdecf5a8dfc1ee669b684ed6e2b2be1"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/glow-study-ends-but-wgs-remains-valuable-for-glioblastoma-patients\/#primaryimage","url":"https:\/\/www.hartwigmedicalfoundation.nl\/wp-content\/uploads\/2025\/09\/GLOW-logo-EN-zwart-scaled.png","contentUrl":"https:\/\/www.hartwigmedicalfoundation.nl\/wp-content\/uploads\/2025\/09\/GLOW-logo-EN-zwart-scaled.png","width":2560,"height":1792},{"@type":"WebSite","@id":"https:\/\/www.hartwigmedicalfoundation.nl\/#website","url":"https:\/\/www.hartwigmedicalfoundation.nl\/","name":"Hartwig Medical Foundation","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hartwigmedicalfoundation.nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.hartwigmedicalfoundation.nl\/#\/schema\/person\/8cdecf5a8dfc1ee669b684ed6e2b2be1","name":"Aleid Eigenraam","url":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/author\/aleid\/"}]}},"_links":{"self":[{"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/posts\/9912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/comments?post=9912"}],"version-history":[{"count":2,"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/posts\/9912\/revisions"}],"predecessor-version":[{"id":9914,"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/posts\/9912\/revisions\/9914"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/media\/9904"}],"wp:attachment":[{"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/media?parent=9912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/categories?post=9912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hartwigmedicalfoundation.nl\/en\/wp-json\/wp\/v2\/tags?post=9912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}